Cochrane · systematic review · CD013647
Siponimod for multiple sclerosis
Cao, L, Li, M, Yao, L, et al. · Cochrane Database of Systematic Reviews · 2021 · Cochrane Library
Multiple Sclerosis and Rare Diseases of the CNSAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
7
current version
GRADE rated
7
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 2 · 28.6%Low 5 · 71.4%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Siponimod compared with placebo for multiple sclerosis
Population: people with multiple sclerosis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Number of participants with relapses at 6 months Siponimod vs placebo | RR 0.38 [0.15, 1] | 1 study · 94 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
Participants with disability worsening at 6 months Siponimod vs placebo | RR 0.78 [0.65, 0.94] | 1 study · 1641 participants | Low Downgraded: risk of bias, indirectness |
Number of participants who withdrew due to AEs at 6 months Siponimod vs placebo | RR 1.52 [0.85, 2.71] | 2 studies · 1739 participants | Low Downgraded: risk of bias, indirectness |
Annualised relapse rate Siponimod vs placebo | RR 0.43 [0.34, 0.56] | 2 studies · 1739 participants | Low Downgraded: risk of bias, indirectness |
Mean number of gadolinium‐enhancing lesions on T1‐weighted brain MRI image at 6 months Siponimod vs placebo | RR 0.14 [0.1, 0.19] | 1 study · 1641 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
Mean number of new lesions or enlarged pre‐existing lesions on T2‐weighted brain MRI images at 6 months Siponimod vs placebo | RR 0.19 | 2 studies · 1739 participants | Low Downgraded: risk of bias, indirectness |
Number of participants with at least one SAE at 6 months Siponimod vs placebo | RR 1.8 [0.37, 8.77] | 2 studies · 1739 participants | Low Downgraded: risk of bias, indirectness |